Drug
Vk5211
Vk5211: highest development phase Phase 2, developed by Viking Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Viking Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| VK5211 NCT02578095 | Phase 2 | Hip Fractures |
Latest
No recent events.
Follow Vk5211 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.